S100P and prostate adenocarcinoma: In pan-cancer, it was found that S100P was more highly expressed in breast cancer(BRCA), cervical cancer(CESC), colon cancer(COAD), liver cancer(LIHC), lung adenocarcinoma(LUAD), pancreatic cancer(PAAD), rectal cancer(READ), endometrioid cancer(UCEC), and uterine carcinosarcoma(UCS), but lower in large B-cell lymphoma(DLBC), prostate cancer(PRAD), melanoma(SKCM), thyroid cancer(THCA), and thymoma(THYM) (Fig. 1A), especially in PAAD (Figure S1).